Bicocca Open Archive

Logo unimib boa
COLOMBO, NICOLETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.447
AS - Asia 18.399
EU - Europa 10.452
SA - Sud America 3.156
AF - Africa 291
OC - Oceania 54
Continente sconosciuto - Info sul continente non disponibili 29
AN - Antartide 1
Totale 58.829
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.845
SG - Singapore 6.115
CN - Cina 3.867
HK - Hong Kong 3.636
VN - Vietnam 2.937
RU - Federazione Russa 2.555
BR - Brasile 2.534
IT - Italia 1.760
IE - Irlanda 1.383
UA - Ucraina 1.057
SE - Svezia 984
DE - Germania 785
GB - Regno Unito 586
CA - Canada 443
KR - Corea 397
FI - Finlandia 336
ID - Indonesia 322
AT - Austria 274
AR - Argentina 265
IN - India 240
FR - Francia 184
NL - Olanda 180
JP - Giappone 155
BD - Bangladesh 149
ZA - Sudafrica 129
EC - Ecuador 126
TR - Turchia 126
MX - Messico 118
IQ - Iraq 92
DK - Danimarca 61
ES - Italia 60
PY - Paraguay 47
AU - Australia 45
CO - Colombia 45
VE - Venezuela 45
PK - Pakistan 44
MA - Marocco 40
UZ - Uzbekistan 39
CL - Cile 38
PL - Polonia 36
KE - Kenya 34
SA - Arabia Saudita 34
TW - Taiwan 32
BE - Belgio 30
EG - Egitto 28
IR - Iran 25
PE - Perù 24
RO - Romania 24
UY - Uruguay 22
EU - Europa 20
CH - Svizzera 19
AE - Emirati Arabi Uniti 18
BG - Bulgaria 16
IL - Israele 16
JO - Giordania 16
LT - Lituania 15
NP - Nepal 15
PT - Portogallo 15
CZ - Repubblica Ceca 14
MY - Malesia 14
TN - Tunisia 14
DZ - Algeria 13
LB - Libano 13
PH - Filippine 13
RS - Serbia 13
AZ - Azerbaigian 12
GR - Grecia 11
KZ - Kazakistan 10
QA - Qatar 10
TH - Thailandia 10
NO - Norvegia 8
OM - Oman 8
A2 - ???statistics.table.value.countryCode.A2??? 7
AL - Albania 7
BO - Bolivia 7
DO - Repubblica Dominicana 7
JM - Giamaica 7
MD - Moldavia 7
NZ - Nuova Zelanda 7
SN - Senegal 7
KG - Kirghizistan 6
MK - Macedonia 6
BY - Bielorussia 5
HU - Ungheria 5
PS - Palestinian Territory 5
TT - Trinidad e Tobago 5
CR - Costa Rica 4
MU - Mauritius 4
SY - Repubblica araba siriana 4
BA - Bosnia-Erzegovina 3
ET - Etiopia 3
GA - Gabon 3
GT - Guatemala 3
HN - Honduras 3
HR - Croazia 3
LU - Lussemburgo 3
NG - Nigeria 3
NI - Nicaragua 3
PA - Panama 3
AO - Angola 2
Totale 58.778
Salva come PNG Salva come JPEG
Città #
Hong Kong 3.613
Ann Arbor 3.338
Singapore 3.137
Woodbridge 2.684
Fairfield 2.357
Houston 1.901
Ashburn 1.542
Dublin 1.301
Jacksonville 1.196
Wilmington 1.023
Ho Chi Minh City 938
Seattle 896
Hefei 866
Cambridge 787
Dearborn 736
Chandler 695
New York 685
Hanoi 664
Princeton 639
Santa Clara 466
Milan 435
Seoul 371
Dallas 362
Beijing 337
Los Angeles 332
The Dalles 318
Lawrence 315
Moscow 306
Altamura 290
Frankfurt am Main 285
Nanjing 280
Chicago 264
Jakarta 246
São Paulo 207
Lachine 202
Vienna 197
Buffalo 175
Guangzhou 165
San Diego 143
Shanghai 137
Nuremberg 136
Andover 125
Boardman 123
Haiphong 117
London 112
Toronto 104
Dong Ket 96
Rome 92
Council Bluffs 91
Nanchang 87
Rio de Janeiro 81
Da Nang 76
Tokyo 76
Hamburg 75
Shenyang 75
Salt Lake City 70
Tianjin 70
Changsha 69
Falls Church 69
Biên Hòa 68
Helsinki 67
Hebei 60
Quận Bình Thạnh 59
Ha Long 58
Ottawa 57
Norwalk 53
Hải Dương 49
Johannesburg 49
Mountain View 49
Guayaquil 48
Hangzhou 47
Ninh Bình 47
Tampa 47
Columbus 46
Elk Grove Village 45
Jiaxing 45
Lappeenranta 45
Curitiba 44
Jinan 43
Brasília 42
Thái Nguyên 42
Dhaka 41
Redmond 41
Kent 40
Quito 40
Can Tho 39
Tashkent 39
Huizen 38
Belo Horizonte 37
Porto Alegre 37
Munich 36
Mexico City 35
Zhengzhou 35
Amsterdam 33
Bắc Ninh 32
Phoenix 32
San Jose 32
Fremont 31
Salvador 31
Kunming 30
Totale 38.364
Salva come PNG Salva come JPEG
Nome #
ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up 578
Single-Agent Trabectedin Versus Physician's Choice Chemotherapy in Patients With Recurrent Ovarian Cancer With BRCA -Mutated and/or BRCAness Phenotype: A Randomized Phase III Trial 567
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 546
Early CAR- CD4+ T-lymphocytes recovery following CAR-T cell infusion: A worse outcome in diffuse large B cell lymphoma 389
Erratum: Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2017) 28 (iv72-iv83) DOI: 10.1093/annonc/mdx220) 330
Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer 321
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 311
Harmonising clinical trials within the Gynecologic Cancer InterGroup: Consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference 307
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer 296
Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer 284
ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease 282
CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells 279
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 262
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer 244
Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study 244
Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series 243
FORWARD I: A Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer 239
ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease 236
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study 224
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO-the MIMOSA study 222
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial 222
Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation 219
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 218
Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12 217
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale 214
Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients 204
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 201
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study 199
The disposition of carboplatin in ovarian cancer patients 199
Ultrasonographic diagnosis and longitudinal follow-up of recurrences after conservative surgery for borderline ovarian tumors 199
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis 196
A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups 196
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer 196
Diffusion-weighted MR imaging in assessing cervical tumour response to nonsurgical therapy 195
Robotic Versus Open Radical Hysterectomy in Women With Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy: A Single-institution Experience of Surgical and Oncologic Outcomes 195
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 194
Effect of a streptococcal preparation (OK432) on natural killer activity of tumour-associated lymphoid cells in human ovarian carcinoma and on lysis of fresh ovarian tumour cells 193
Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial 193
Neoadjuvant chemotherapy in cervical cancer: An update 193
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial 193
Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis 192
Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer 191
Lack of activity of cyclophosphamide in ovarian cancer patients refractory to cis-dichlorodiammine platinum 191
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial 191
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the gynecologic cancer intergroup 189
Low-dose oral etoposide in epithelial cancer of the ovary 189
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 188
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics 187
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale 186
A reassessment of the role of second-look laparotomy in advanced ovarian cancer 186
Risk-reducing salpingo-oophorectomy in women at higher risk of ovarian and breast cancer: A single institution prospective series 186
Chemo-conization in early cervical cancer 185
Peripheral neurotoxicity of taxol in patients previously treated with cisplatin 185
Platinum-based neoadjuvant chemotherapy followed by radical surgery for cervical carcinoma international federation of gynecology and obstetrics stage IB2-IIB 185
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer 185
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer 185
Reply to M.L. Friedlander et al 184
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 184
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion 183
DR antigen expression on ovarian carcinoma cells does not correlate with their capacity to elicit an autologous proliferative response 183
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens 183
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial 182
Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer 181
Aggressive angiomyxoma of the vulva 180
The role of surgery in gestational trophoblastic disease 180
Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells 179
Trabectedin as single agent in relapsed advanced ovarian cancer: Results from a retrospective pooled analysis of three phase II trials 179
Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients 179
BRCA1/2 molecular assay for ovarian cancer patients: A survey through Italian departments of oncology and molecular and genomic diagnostic laboratories 179
Methotrexate with citrovorum factor in low-risk gestational trophoblastic tumor 178
Neoadjuvant chemotherapy prior to pelvic exenteration in patients with recurrent cervical cancer: Single institution experience 178
Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients 177
Pure ovarian immature teratoma, a unique and curable disease: 10 years' experience of 32 prospectively treated patients 177
Tumor-derived chemotactic factor(s) from human ovarian carcinoma: evidence for a role in the regulation of macrophage content of neoplastic tissues 177
Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: Results of a randomized, double-blind, phase 2, parallel-arm study 177
Antibody-dependent and -independent cytotoxicity of human mononuclear phagocytes: defective stimulation of tumoricidal activity in milk macrophages 177
Defective natural killer activity within human ovarian tumors: Low numbers of morphologically defined effectors present in situ 176
Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients 176
Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study 176
Robotic Surgery: Changing the Surgical Approach for Endometrial Cancer in a Referral Cancer Center 175
Early oral versus "traditional" postoperative feeding in gynecologic oncology patients undergoing intestinal resection: A randomized controlled trial 175
Cisplatin, vinblastine, and bleomycin combination chemotherapy in metastatic granulosa cell tumor of the ovary 175
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 175
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy 173
Treatment of advanced ovarian cancer (OC): A randomized trial comparing different platinum (P) combinations 173
Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge 173
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study 173
Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval 172
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients 172
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: A randomised phase 2 trial 172
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status 171
Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer 170
Optimal treatment of early-stage ovarian cancer 169
Hydrological, thermal and chemical influence of an intact rock glacier discharge on mountain stream water 168
Pre-chemotherapy hemoglobin levels and survival in patients with advanced epithelial ovarian cancer who received a first-line taxane/platinum-based regimen: Results of a multicenter retrospective Italian study 168
Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis 168
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer 168
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study 166
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial 166
Fertility-Sparing Options in Young Women with Cervical Cancer 165
Totale 21.153
Salva come PNG Salva come JPEG
Categoria #
all - tutte 218.013
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 218.013
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.786 0 0 0 0 0 396 481 511 396 478 199 325
2021/20223.002 181 245 348 237 184 196 168 209 186 250 231 567
2022/20234.033 665 1.028 274 226 247 729 59 327 243 66 95 74
2023/20244.164 98 105 176 111 637 1.033 755 107 525 117 68 432
2024/202513.024 713 1.688 492 616 1.039 526 998 405 1.286 1.616 1.088 2.557
2025/202616.206 3.666 3.062 2.373 3.235 2.689 1.181 0 0 0 0 0 0
Totale 60.260